menu
    • menu
    [{"orgOrder":0,"company":"Bukwang Pharmaceutical Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Clevudine","moa":"Protein P","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bukwang Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bukwang Pharmaceutical Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bukwang Pharmaceutical Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"HebaBiz Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Clevudine","moa":"HBV DNA chain replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HebaBiz Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"HebaBiz Biotech \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"HebaBiz Biotech \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Clevudine

    Menu

    Clevudine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HebaBiz Biotech

                            China arrow
                            IOPC
                            Not Confirmed

                            HebaBiz Biotech

                            China arrow
                            IOPC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clevudine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            R&D Milestone: HebaBiz Biotech's Application for Phase III clinical trial in China for Clevudine (L-FMAU), An ...

                            Details : L-FMAU (Clevudine) is a synthetic β-L nucleoside analogue introduced from Yale University and HebaBiz Biotech obtained its exclusive license for anti-hepatitis B virus in Greater China. L-FMAU as a new generation best-in-class anti-HBV new drug.

                            Product Name : L-FMAU

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 15, 2021

                            Lead Product(s) : Clevudine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bukwang Pharmaceutical Co., Ltd

                            South Korea arrow
                            IOPC
                            Not Confirmed

                            Bukwang Pharmaceutical Co., Ltd

                            South Korea arrow
                            IOPC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clevudine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Leukavir, an Antiviral Agent for Bukwang Pharm, Confirmed the Effect on New Coronavirus

                            Details : Levovir (clevudine) was found to be effective on virus isolated from the specimens of Korean Coronavirus Infectious Disease-19 (COVID-19) patients, similar to calletra used for the treatment of COVID-19 in vitro.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 03, 2020

                            Lead Product(s) : Clevudine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth